Orolia USA

Vaccinex, Inc. is a pioneering biopharmaceutical company based in Rochester, NY, that is dedicated to developing innovative treatments for cancer and neurologic diseases. Their lead drug candidate, pepinemab, is a first-in-class anti-semaphorin antibody that blocks the activity of SEMA4D, a potent biological effector believed to inhibit immune infiltration in tumors and trigger neuroinflammation in the brain. With a powerful therapeutic antibody discovery platform called ActivMAb, Vaccinex aims to create new drugs and expand their pipeline through strategic collaborations. Vaccinex's unique approach to targeting SEMA4D has the potential to increase immune activity against tumors and reprogram pathogenic immune mechanisms in chronic neurological disorders like Alzheimer's and Huntington's disease. In addition to their clinical programs, Vaccinex is actively exploring the combination of pepinemab with checkpoint inhibitors in immuno-oncology, showing promising results in enhancing T-cell infiltration and reducing immunosuppressive cells in tumors. With global commercial and development rights to pepinemab, Vaccinex is committed to advancing the field of medicine and improving patient outcomes.Generated from the website

Welcome to Trec Environmental Environmental Remediation Trec Environmental Inc ( TREC ) provides environmental remediation services for both hazardous and non-hazardous waste sites. TREC implements effective strategies designed by engineering firms to meet site investigation and clean up needs.